Summary & Overview
HCPCS Level II S0128: Injection, follitropin beta, 75 IU
HCPCS Level II code S0128 denotes an injection of follitropin beta, 75 IU, a recombinant follicle-stimulating hormone commonly used in assisted reproductive treatments. Nationally, this code matters because it captures a discrete medication dose used in fertility protocols, affecting billing for reproductive endocrinology clinics, outpatient infusion centers, and payers covering fertility services. Coverage, prior authorization, and coding consistency for injectable fertility agents influence patient access and provider billing workflows.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of what S0128 represents clinically, payer coverage patterns, and common billing considerations tied to injectable fertility medications. The publication also summarizes benchmark metrics where available, common modifier usage patterns, and relevant policy or reimbursement updates impacting billing for follitropin beta injections. Clinical context explains typical administration settings and service implications for outpatient fertility care.
This summary equips billing managers, revenue cycle leaders, and clinical administrators with the code-level context needed to align documentation and claims processes for fertility medication injections.
Billing Code Overview
HCPCS Level II code S0128 represents an injection of follitropin beta, 75 IU. This code describes a medication administration service delivering a specific unit dose of follitropin beta, a recombinant follicle-stimulating hormone used in fertility treatment protocols.
-
Service type: Medication injection (reproductive endocrinology/assisted reproductive therapy)
-
Typical site of service: Outpatient clinic, fertility center, or ambulatory infusion/injection suite
Clinical & Coding Specifications
Clinical Context
A 33-year-old woman with a history of anovulatory infertility due to polycystic ovary syndrome (PCOS) presents to a reproductive endocrinology clinic for controlled ovarian stimulation as part of an in vitro fertilization (IVF) cycle. The clinician prescribes daily subcutaneous injections of follicle-stimulating hormone preparation S0128 (follitropin beta, 75 IU) to stimulate multifollicular development. Baseline transvaginal ultrasound and serum estradiol are obtained prior to initiation. The patient self-administers S0128 at home each morning after instruction by clinic nursing staff; clinic visits occur every 2–3 days for transvaginal monitoring and estradiol measurements. Dose adjustments are made based on follicular response. When adequate follicle size and estradiol levels are reached, ovulation trigger and oocyte retrieval are scheduled in the ambulatory surgical center. Billing for S0128 typically occurs on each day of administration or per vial dispensed per the payer's medication billing policies, with documentation of indication, dose, date/time, and patient consent in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard service |